关于燃石医学
燃石医学成立于2014年，专注于为肿瘤精准医疗提供最具临床价值的二代基因测序（NGS）。目前，燃石医学已经针对不同癌种和临床场景开发了32种检测产品，涉及肿瘤靶向和免疫用药伴随检测、肿瘤良恶性检测、微小残留病灶监测、肿瘤复发进展预测和肿瘤敏感性测试。
燃石医学拥有中国第一间由美国CLIA认证的ctDNA和肿瘤组织NGS实验室。公司与全国300多家顶尖医院开展了深度合作，并积累了中国最大的实体瘤基因组数据库之一。
除了提供LDT模式（临床实验室自建项目）的NGS检测服务，燃石医学也是一站式NGS平台解决方案、推进高质量NGS检测落地医院病理科从而惠及更多肿瘤患者的先行者。公司拥有首个获NMPA（中国国家药品监督管理局）批准的NGS检测试剂盒，与安捷伦科技、 珀金埃尔默、Illumina、凯杰以及众多制药公司有战略性合作，将始终致力于开发创新与可靠的NGS检测产品让肿瘤患者临床获益。
About Burning Rock
Founded in 2014, Burning Rock Biotech is specialized in NGS （Next-Generation Sequencing） diagnositcs solutions for precision medicine in oncology. Thus far, Burning Rock has developed 32 products for different cancer types an d clinical applications, ranging from companion diagnostics for targeted therapy an d immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence an d progression prediction, an d tumor susceptibility tests.
Burning Rock has established China’s first CLIA （（Clinical Laboratory Improvement Amendments）-certified NGS laboratory for both ctDNA an d tumor tissue assays. Through deep collaborations with over 300 top provincial an d national hospitals, the company has accumulated one of the largest cancer genomic databases in solid tumors in China.
Besides providing NGS test services in an LDT model, Burning Rock also pioneers in providing one-stop NGS platform solutions an d enabling high-quality NGS tests at hospitals’ pathology labs, which will benefit more patients in the long run. With the first NMPA （National Medical Products Administration）-approved NGS kit in China, strategic collaborations with Agilent, PerkinElmer, Illumina, Qiagen, an d numerous pharmaceutical companies, Burning Rock is decicated to developing innovative an d reliable NGS diagnostics products to benefit cancer patients.
